Nick Luff (pictured), chief financial officer at Relx, which owns medical journal The Lancet, denied there were any imminent plans to relocate.Read More

You might also be interested in reading Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases.